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Abstract: Indolizidines are great-potential bioactive heterocyclic compounds normally prepared 
following multi-step routes. However, to the best of our knowledge, the synthesis of 1-amino 
indolizidines has never been reported. Herein, 1-dialkylamino-3-substituted indolizidines have been 
straightforwardly synthesized using an atom-economy protocol which involves a copper-catalyzed 
three-component synthesis of indolizines followed by heterogeneous catalytic hydrogenation. The latter 
was found to be chemoselective using platinum(IV) oxide as the catalyst at 3.7 atm, providing the 
amino indolizidines in modest-to-high yields (35–95%) and high diastereoselectivity (92:8 to > 99:1). 
It has been experimentally demonstrated that the hydrogenation occurs through the intermediate 
5,6,7,8-tetrahydroindolizine, which contains a pyrrole moiety. Moreover, the diastereomerically pure 1-
dibenzylamino-3-substituted indolizidines could be further transformed into the corresponding mono-
benzylated or fully debenzylated amino indolizidines by selective hydrogenolysis catalyzed by Pt/C or 
Pd/C, respectively, under ambient conditions. 
 
 
 INTRODUCTION 
There is a general upsurge of interest in developing new strategies to effectively obtain saturated N-
heterocycles from readily accessible starting materials. This demand is supported by the potential 
development of new pharmaceuticals related to this type of heterocycles and their natural abundance.1 
Among them, indolizidine alkaloids are widespread in nature and have attracted a great deal of 
attention because of their structural diversity and varied biological activity (Chart 1).2 For instance, 
indolizidine 167B was first found as a minor constituent in the skin secretions of a batrachian of the 
genus Dendrobates,3 whereas (+)-monomorine I was isolated from both Pharaoh’s ant Monomorium 
pharaonis and from bufonid toads of the Melanopbryniscus genus.4 (–)-Tashiromine was first isolated 
from the stems of Maackia Tashiroi (Leguminosae),5a a bush from subtropical Asia, and later on from 
leaves and seeds of the Poecilanthe5b genus and from Ethiopian Crotalaria species.5c Swainsonine was 
first identified in the Australian legume Swainsona canescens6a and, subsequently, as the toxin in 
Astragalus and Oxytropis species that cause locoism in livestock.6b In contrast, the significance of 
swainsonine in the treatment of cancer and in immunology has been reported.6c Indolizidines have also 
played an important role in the synthesis of other natural products.7 
Chart 1. Structure of some naturally occurring indolizidines. 
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  Different synthetic strategies have been developed to construct the indolizidine skeleton according 
to the substitution pattern pursued,8 including: (a) the use of pyrroles as building blocks,9 (b) from α-
aminoacids via stereocontrolled rhodium-catalyzed hydroformylation of N-allylpyrroles,10 (c) based on 
organosulfur and selenium chemistry (i.e., conjugate addition of nitrogen nucleophiles containing ester 
or chloroalkyl substituents to acetylenic sulfones, followed by base-mediated intramolecular alkylation 
or acylation),11 (d) by stereocontrolled cyclic nitrone cycloaddition,12 (e) by addition of allylsilanes to 
N-acyliminium ions,13 (f) by stereoselective conjugate addition reactions,14 (g) through radical 
azidation reactions,15 and (h) through chiral oxazolopiperidone lactams.16 However, despite the 
synthesis of indolizidines by the reduction of indolizines seems to be a direct approach, it has been 
barely documented and limited to some isolated examples.17 Other few reports describe the synthesis of 
indolizidines by heterogeneous catalytic hydrogenation of the pyrrole ring of 5,6,7,8-
tetrahydroindolizines.18 To the best of our knowledge, there is only one systematic study on the 
synthesis of indolizidines by full hydrogenation of indolizines, recently reported by Coelho et al.19 At 
any rate, partial reduction is a common problem encountered, which together with a desirable higher 
diastereoselectivity,20 make the selective hydrogenation of indolizines a challenging objective. 
On the other hand, multicomponent heterocyclic synthesis is a effectual strategy to build diverse and 
complex structures in a sole operation and atom-economy fashion.21 Due to our interest and 
commitment to comprehend the reactivity of transition metal colloids,22 we presented a catalyst 
comprised of oxidized copper nanoparticles supported on activated carbon (CuNPs/C), which was 
easily obtained under soft conditions and highly versatile in the multicomponent click synthesis of 
1,2,3-triazoles in water, using different azido precursors.23 More recently, the same catalyst was shown 
to be effective in the multicomponent synthesis of indolizines from pyridine-2-carbaldehyde 
derivatives, secondary amines and terminal alkynes.24 In this work we also introduce what is, to the 
best of our knowledge, the first example of a 1,3-disubstituted indolizidine bearing an amino group at 
the 1 position, obtained by catalytic hydrogenation of the corresponding indolizine.24a Herein, we wish 
 to present a complete survey on our efforts to develop a straightforward synthesis of 1-amino-3-
substituted indolizidines based on the chemo- and diastereoselective catalytic hydrogenation of 
indolizines (Scheme 1). 
 
Scheme 1. Synthetic sequence toward 1-amino-3-substituted indolizidines. 
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RESULTS AND DISCUSSION 
First, we optimized the catalyst and reaction conditions for the catalytic hydrogenation of indolizines. 
N,N-Dibenzyl-3-phenylindolizin-1-amine (4h) was chosen as the model substrate because its 
hydrogenation was considered more challenging, due to the presence of three carbon-nitrogen bonds 
prone to undergo hydrogenolysis. In addition, the different hydrogenation degree for the five and six- 
membered rings of the indolizine nucleus made the desired transformation more difficult to achieve. In 
 Table 1. Hydrogenation of indolizine 4h using platinum catalysts.a 
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Entry Catalyst Solvent P (H2, atm) t (h) 5h/6h/7h/8h (%)b 
1 PtO2 MeOH-CH2Cl2c 1.0 72 47/-/-/- 
2 PtO2 MeOH-CH2Cl2c 3.7 2 44/7/-/6 
3 PtO2 EtOH 3.7 8 8/2/-/- 
4 PtO2 CH2Cl2 3.7 2 8/-/-/- 
5 PtO2 EtOAc 3.7 2 23/-/-/- 
6 PtO2 EtOAc 3.7 9 26/-/-/- 
7 PtO2 HOAc 1.0 24 39/-/-/- 
8 PtO2 HOAc 3.7 2 65/2/-/21 
9 PtO2 HOAc 3.7 8 26/10/-/5 
10 PtO2 HOAc 5.1 1 48/-/-/- 
11 PtO2d HOAc 3.7 2 40/-/-/12 
12 PtO2 HOAc 1.0e 23 19/24/-/25 
13 PtO2 MeOH-HOAcf 3.7 2 53/-/-/20 
14 PtO2 CH2Cl2-HOAcf 3.7 2 65/13/-/10 
15 Pt(1 wt%)/Al2O3 MeOH-CH2Cl2c 3.7 2 31/-/-/- 
16 Pt(1 wt%)/Al2O3 HOAc 3.7 2 55/-/-/- 
17 Pt(5 wt%)/Al2O3 HOAc 1.0e 20 -/-/-/- 
18 Pt(5 wt%)/CaCO3 HOAc 3.7 3 62/14/-/14 
19 Pt(5 wt%)/CaCO3d HOAc 3.7 3 57/7/-/30 
20 Pt(5 wt%)/CaCO3 HOAc 1.0e 20 10/23/-/36 
21 Pt(5 wt%)/SiO2 HOAc 3.7 3 -/-/-/- 
22 Pt(10 wt%)/C MeOH-CH2Cl2c 3.7 4 24/-/-/- 
23 Pt(10 wt%)/C HOAc 3.7 2 56/-/-/- 
24 Pt(5 wt%)/C HOAc 3.7 3 68/6/-/8 
25 Pt(5 wt%)/Cd HOAc 3.7 3 52/7/-/15 
26 Pt(5 wt%)/C HOAc 1.0e 23 16/19/-/9 
27 Pt(5 wt%)/C HOAc 1.0e 7g 30/14/-/26 
28 Pt(5 wt%)/C HOAc 1.0e 48g 22/46/-/- 
29 Pt(5 wt%)/C MeOH-HOAcc 3.7 3 9/5/-/- 
aReaction conditions: 4h (0.3 mmol), catalyst (10 mol%), solvent (3.0 mL) and H2 at rt. bConversion 
determined by GLC. c3:1 v/v. d5 mol%. eIn balloon. f1:1 v/v. gReaction at 50 ºC. 
 principle, all reactions were carried out at room temperature with 10 mol% of a platinum catalyst in 
different solvents or mixtures of solvents at various hydrogen pressures (Table 1); MeOH-CH2Cl2 or 
MeOH-HOAc mixtures favored solubilization of the starting indolizine with respect to the use of only 
MeOH. As regards the use of PtO2 as catalyst (Table 1, entries 1–14), higher pressure (3.7 atm) and 
shorter reaction time (2 h) increased the conversion into the desired indolizidine 5h, particularly in the 
presence of HOAc as solvent (Table 1, entry 8); variable amounts of the mono-debenzylated 
indolizidine 6h and a semihydrogenation product (at this stage postulated to be 8h) were also formed. 
Longer reaction time (8 h) at the same pressure had a detrimental effect on the conversion due to 
additional by-product formation (Table 1, compare entries 8 and 9). The combination of HOAc with 
either MeOH or CH2Cl2 gave quite good results but did not improve those reached with PtO2 (Table 1, 
entries 13 and 14). Then, we explored the behavior of different platinum-based supported catalysts. The 
highest conversions were achieved with Pt(5 wt%)/CaCO3 and Pt(5 wt%)/C (Table 2, entries 18 and 
24, respectively), likewise as above, when pressure (3.7 atm) and short reactions time (3 h) were 
applied in HOAc, with the concomitant formation of 6h and 8h. As in the case of PtO2 (Table 1, entry 
11), lower catalyst loading (5 mol%) in the supported catalysts led to a decrease in the conversion 
though of a lower magnitude compared to the former (Table 1, entries 19 and 25). 
Other metal catalysts were also tested with the aim to minimize by-product formation (Table 2). Pd(10 
wt%)/C provided a moderate conversion into 5h at ambient pressure and prolonged stirring in MeOH, 
together with a substantial amount of mono-debenzylated 6h (Table 2, entry 1); higher hydrogen 
pressure shortened the reaction time but did not improve the conversion (Table 2, entry 2). An 
interesting effect of the pressure was noticed with Pd(20 wt%)/C in HOAc, leading to 6h at 3.7 atm or 
7h at ambient pressure with some selectivity (Table 2, entries 4 and 5). Unfortunately, any possibility 
for directly transforming the starting indolizine 4h into 6h or 7h by the choice of the pressure vanished 
because of the low diastereoselectivity attained in both cases (Table 2, footnotes d and g). This lack of 
diastereoselectivity was also manifested with the deployment of Pd(5 wt%)/CaCO3 which, conversely, 
 was highly chemoselective towards the formation of 6h (Table 2, entry 7). Other catalysts, either 
heterogeneous [Pd(OH)2/C, Rh(5 wt%)/C and Ru(5 wt%)/C] or homogeneous {[Rh(COD)Cl]2, 
[RuCl2(p-cymene)]2 and [Ir(COD)Cl]2}, and/or reaction conditions furnished complex reaction 
mixtures (Table 2, entries 6, 8, 9 and 11), no product (Table 2, entries 12–14) or a certain amount of N-
benzylidene-3-phenylindolizin-1-amine, i.e. the imine of mono-debenzylated 6h (Table 2, entries 3, 16 
and 17). 
 
Table 2. Hydrogenation of indolizine 4h using other metal catalysts.a 
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Entry Catalyst Solvent P (H2, atm) t (h) 5h/6h/7h/8h (%)b 
1 Pd(10 wt%)/C MeOH 1.0 48 64/19/-/- 
2 Pd(10 wt%)/C MeOH 3.7 7 48/4/-/- 
3 Pd(10 wt%)/C HOAc 3.7 2 -c 
4 Pd(20 wt%)/C HOAc 3.7 3 -/92d/8/- 
5 Pd(20 wt%)/C HOAc 1.0e 23 -/16f/64g/- 
6 Pd(5 wt%)/CaCO3 HOAc 3.7 3 -h 
7 Pd(5 wt%)/CaCO3 HOAc 1.0e 20 -/81i/-/- 
8 Pd(OH)2/C MeOH 1.0 22 -h 
9 Pd(OH)2/C MeOH-CH2Cl2j 1.0 13 -h 
10 Pd(OH)2/C MeOH-CH2Cl2j 3.7 6 -/27/-/- 
11 Pd(OH)2/C MeOH-CH2Cl2k 1.0 15 -h 
12 Rh(5 wt%)/C HOAc 1.0e 20 - 
13 Rh(5 wt%)/C HOAc 3.7 3.5 - 
14 Ru(5 wt%)/C HOAc 3.7 4 - 
15 [Rh(COD)Cl]2 MeOH-CH2Cl2j 3.7 10 -l 
16 [RuCl2(p-cymene)]2 i-PrOH 3.7 8 -m 
17 [Ir(COD)Cl]2 HOAc 3.7 8 -n 
aReaction conditions: 4h (0.3 mmol), catalyst (10 mol%), solvent (3.0 mL) and H2 at rt. bConversion 
determined by GLC. cMonodebenzylated 4h (25%) and its imine (35%). d55:45 dr. eIn balloon. 
f62:38dr. g64:19:17 dr. hComplex mixture. i47:44:9 dr. jMeOH-CH2Cl2 (3:1 v/v). kMeOH-CH2Cl2 (1:1 
 v/v). lUnidentified product (29%). mImine of monodebenzylated 4h (12%). nImine of 
monodebenzylated 4h (4%). 
 
From this optimization study it can be concluded that PtO2 and Pt(5 wt%)/C are the best catalysts in 
terms of conversion and selectivity (Table 1, entries 8 and 24, respectively). Given the heterogeneous 
nature of both catalysts, they are potentially recoverable and recyclable.25 PtO2 could be easily reused 
by decantation, supernatant removal and catalyst washing in the same hydrogenation flask. In contrast, 
further manipulation and centrifugation were required for Pt(5 wt%)/C. For comparative purposes, all 
recycling experiments were conducted at 3.7 atm for 2 h (Figure 1). Catalyst reutilization was found to 
be more efficient with PtO2 than with Pt(5 wt%)/C (60% versus 36% in the second cycle). The 
catalytic activity of both catalysts decreased in subsequent cycles: 35 and 30% for PtO2 and <10% for 
Pt(5 wt%)/C, albeit better conversions would be expected for longer reaction times. In addition to this, 
we also observed that the catalytic performance of Pt(5 wt%)/C with substrates other than 4h was lower 
than with PtO2.26 In view of the aforementioned results, the catalytic system of choice was that 
composed of PtO2 (10 mol%) in HOAc at 3.7 atm H2 (Table 1, entry 8). 
 
 
FIGURE 1. Catalyst recycling experiments in the hydrogenation of 4h (3.7 atm H2, 2 h). 
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 In order to study the substrate scope, the optimized catalyst and reaction conditions were applied to a 
variety of indolizines 4, derived from pyridine-2-carbaldehyde (1a), secondary amines (2) and terminal 
alkynes (3), producing the expected indolizidines 5 in modest-to-high yields and with high-to-excellent 
diastereoselectivity (Table 3). The yield and diastereoselectivity were found to be dependent on the 
substituents at the 1 and 3 positions, with the amino group at the 1 position apparently exerting a 
stronger effect. For instance, the indolizines derived from piperidine and arylacetylenes were isolated 
in lower yields, with the lowest diastereoselectivity been recorded for the phenylacetylene derivative 
(5a). The diastereomeric ratio was improved when a para substituent was present in the arylacetylene-
derived moiety while at the same time maintaining the 1-piperidinyl group (Table 3, compare 5a with 
5b and 5c). Fortunately, purification by column chromatography allowed the isolation of 5a and 5b as 
single diastereoisomers. Better yield and excellent diastereoselectivity were observed when changing 
the 1-piperidinyl into a 1-morpholino group (Table 3, compare 5a with 5d). In general, the results with 
acyclic amines were better than those with the cyclic counterparts concerning all, the yield, the 
diastereoselectivity and the reaction time. The diastereoselectivity increased when increasing the steric 
hindrance of the secondary amine (Table 3, compare 5e and 5f with 5g and 5h). The indolizidines 
derived from dibenzylamine followed a similar trend to that of dibutylamine (5g), being generally 
obtained in relatively short hydrogenation reaction times and as single diastereoisomers (Table 3, 5h-
5m). This remarkable behavior was displayed irrespective of the substituent at the 3 position of the 
indolizidine nucleus, including aryl substituents with electron-neutral (Table 3, 5h and 5i), -releasing 
(Table 3, 5j) and -withdrawing groups (Table 3, 5k and 5l), as well as aliphatic substituents (Table 3, 
5m). 
We endeavored to extend this method to more demanding indolizines in order to validate its 
applicability. Such is the case of N,N-dibutyl-1-phenylpyrrolo[1,2-a]quinolin-3-amine (4n), a benzo-
fused indolizine coming from the coupling of quinoline-2-carbaldehyde (1b), dibutylamine (2e) and 
phenylacetylene (3a). It is worthy of note that its catalytic hydrogenation failed under the standard  
 Table 3. Synthesis of the indolizidines 5.a 
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aReaction conditions: 4 (0.5 mmol), PtO2 (10 mol%), HOAc (3 mL), H2 (3.7 atm), rt; reaction time and 
isolated yield in parentheses; diastereomeric ratio in brackets determined by GC-MS from the reaction 
crude. bDiastereomeric ratio after purification by column chromatography. cReaction at 4.1 atm. 
 
 pressure and that a slightly higher pressure was necessary to initiate the reaction. Consequently, the 
latter was found to be more chemoselective at lower than at higher conversions, with an increase of by- 
product formation in the second case. The scant yield of the expected hexahydropyrrolo[1,2-a]quinolin-
3-amine 5n was compensated for the high diastereomeric ratio reached; the presence of the fused 
benzene in the tricyclic indolizine core did not vary the stereochemical outcome with respect to the 
bicyclic counterparts. We went one step further by dealing with the hydrogenation of the trisubstituted 
indolizine 4o, the precursors of which were 6-methylpyridine-2-carbaldehyde (1c), dibenzylamine (2f) 
and phenylacetylene (3a). In this case, a short reaction time was more convenient to minimize by-
product formation. It was gratifying to know that, though in modest isolated yield, the four-stereocenter 
indolizidine 5o could be obtained with very high diastereoselectivity. 
In some cases, by-products derived from the partial hydrogenation of the indolizine nucleus were 
detected in minor amounts. This fact, together with the relative high polarity of the indolizidines, made 
purification by column chromatography troublesome and accounted for some of the lower isolated 
yields recorded. 
We were delighted to confirm that the indolizidine 5h could be obtained from pyridine-2-
carbaldehyde (1a), dibenzylamine (2f) and phenylacetylene (3a), without the need to isolate the 
intermediate indolizine (avoiding the corresponding work-up and purification) in a slightly higher yield 
than that obtained from the isolated indolizine (70 versus 65%, Scheme 2). Therefore, this method 
represents a straightforward access into a new type of stereodefined indolizidines with three (or four) 
stereocenters. 
 
 
 
 
 
 Scheme 2. One-pot type synthesis of indolizidine 5h. 
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Secondary amines are versatile nitrogenated compounds with multiple applications in organic 
chemistry as, for example, as organocatalysts,27 as Lewis bases (e.g., for the activation of electron-
deficient olefins)28 or as building scaffolds for multicomponent reactions,29 among many others. On the 
other hand, in organic chemistry, it is desirable that the selective conversion of a single starting 
material into two or more different products can be accomplished by the selection of the catalyst.30 In 
this vein, attempts to directly transform indolizine 4h into the mono-benzylated secondary amine 6h 
were found to be successful in terms of conversion under palladium catalysis; regretfully, the 
diastereoselectivity of these reactions was too low (Table 2, entries 4 and 7, footnotes d and i). Then, 
we decided to take advantage of the presence of two benzyl groups in the indolizidines 5h-5m and 5o 
to investigate the possibilities of effecting selective hydrogenolyses, leading to secondary amines 6 or 
primary amines 7, through mono- and di-debenzylation processes, respectively. 
Taking into account the information in tables 1 and 2, four catalysts were considered for this study, 
including platinum and palladium catalysts, using indolizidine 5h as the starting material (Table 4). As 
a general trend, platinum catalysts provided the mono-debenzylated product 6h whereas the palladium 
catalyst favoured the full debenzylated product 7h. A significant effect of the hydrogen pressure was 
also discerned, with ambient pressure resulting in higher conversions and less formation of side 
 products. Prolonged stirring was recommended in both cases because did not alter the high selectivity 
attained with the platinum catalysts [Pt(5 wt%)/C and PtO2] (Table 4, entries 3 and 4) and guaranteed 
the full hydrogenolysis with Pd(20 wt%)/C (Table 4, compare entries 7 and 8). 
 
Table 4. Optimization of the hydrogenolysis of 5h. 
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Entry Catalyst P (H2, atm) t (h) 6h/7h (%)b 
1 Pt(5 wt%)/C 3.7 2 15/- 
2 Pt(5 wt%)/C 3.7 6 31/- 
3 Pt(5 wt%)/C 1.0c 22 61/- 
4 PtO2 1.0c 17 83/- 
5 Pt(5 wt%)/CaCO3 1.0c 16 59/- 
6 Pd(20 wt%)/C 3.7 2 31/- 
7 Pd(20 wt%)/C 1.0c 7 6/77 
8 Pd(20 wt%)/C 1.0c 23 -/82 
aReaction conditions: 5h (0.3 mmol), catalyst (10 mol%), HOAc (3.0 mL) and H2 at rt. bConversion 
determined by GLC. cIn balloon. 
 
The optimized conditions were first applied to the selective mono-debenzylation of some of the 
indolizidines 5h-5m. As representative examples, indolizidines derived from aromatic alkynes of 
diverse electronic nature (neutral, rich and deficient ones), as well as from aliphatic alkynes, were 
converted into the monobenzylated counterparts 6 in moderate-to-high yields (Table 5). Although both 
catalysts, PtO2 and Pt(5 wt%)/C selectively catalyzed the mono-debenzylation reaction at ambient 
hydrogen pressure and temperature, the yields were slightly higher when the former was utilized for 5h 
and 5j, and the latter for 5l and 5m. 
 
 Table 5. Mono-debenzylation of indolizidines 5.a 
6m
23 h, 81%c
>99:1 dr
NHBn
N
9
6j
24 h, 72%b
>99:1 dr
NHBn
N
OMe
H
H
6h 
17 h, 68%b
>99:1 dr
NHBn
N
Ph
H
N
N Bn
Bn
R3
N
N H
Bn
R3
5 6
10 mol% Pt/C or PtO2
HOAc, H2
 
(1 atm), rt
H
6l
19 h, 65%c
>99:1 dr
NHBn
N
CF3
H
H
 
aReaction conditions: 5 (0.3 mmol), catalyst (10 mol%), HOAc (3.0 mL) and H2 (1 atm) at rt; isolated 
yield after purification by preparative TLC (hexane/EtOAc 6:4); conversions into 6 were in the range 
82->99%); diastereomeric ratio determined by GC-MS from the reaction crude. bReaction catalyzed by 
PtO2. cReaction catalyzed by Pt(5 wt%)/C. 
 
When the same substrates, as above, were submitted to hydrogenolysis catalyzed by Pd(20 wt%)/C at 
ambient hydrogen pressure and temperature, the corresponding free amino indolizidines 7 were 
produced in high yields as a result of a di-debenzylation process (Table 6). It is noteworthy that the 
original stereochemical integrity of the indolizidines was unaffected during the hydrogenolyses leading 
to the desired products as single diastereomers. 
 Table 6. Di-debenzylation of indolizidines 5.a 
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aReaction conditions: 5 (0.3 mmol), Pd(20 wt%)/C (10 mol%), HOAc (3.0 mL) and H2 (1 atm) at rt; 
conversions into 7 were in the range 73->99%. Compounds 7h and 7l were purified by preparative 
TLC (EtOAc). Compounds 7j and 7m did not require any further purification. Diastereomeric ratio 
determined by GC-MS from the reaction crude. 
 
The stereochemistry of the indolizidines 5 was originally proposed on the basis of 2D-NMR 
experiments conducted for 5d, 5h, 5n and 5o (Figure 2) and, later on, unequivocally established by X-
ray crystallographic analysis of compound 5a (Figure 3).31 In view of these data, the major 
diastereoisomer obtained in the catalytic hydrogenation of the indolizines is that resulting from the 
addition of hydrogen to the same face of the indolizine nucleus. 
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FIGURE 2. Selected 1H-1H correlations from NOESY experiments. 
 
 
FIGURE 3. X-ray structure of compound 5a. 
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 Finally, we were intrigued to know about the hydrogenation pathway and the structure of any possible 
semihydrogenated intermediate. With this purpose in mind, indolizine 4a was hydrogenated under the 
standard conditions but for a shorter reaction time. These intermediates were found to be rather elusive 
because of their minor formation and high tendency to over-hydrogenation. Notwithstanding these 
added difficulties, we managed to isolate a certain amount of the 5,6,7,8-tetrahydroindolizine 8a, which 
confirmed the preferential hydrogenation of the six-membered ring of the indolizine nucleus. Further 
hydrogenation of 8a gave rise to the fully reduced indolizidine 5a with the same stereoselectivity as 
above. These results lend weight to the argument that the stereochemistry of the indolizidines is fixed 
in a second stage, where all hydrogen atoms are delivered from the catalyst to the same face of the 
pyrrole ring in 8a (Scheme 3). 
 
Scheme 3. Sequential hydrogenation of the indolizine 4a and hydrogenation model of 8a. 
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 CONCLUSION 
A series of 1-amino substituted indolizidines have been synthesized from readily available indolizines 
by heterogeneous catalytic hydrogenation. By the choice of the catalyst (PtO2, Pt/C or Pd/C), tertiary, 
secondary or primary amino-substituted indolizidines are selectively produced in modest-to-excellent 
yields (35–95%), mostly, as single diastereomers (with three or four stereocenters). Experimental 
evidence supports the indolizine hydrogenation occurring through the pyrrolic intermediate 5,6,7,8-
tetrahydroindolizine. Furthermore, the indolizidine synthesis can be sequentially and successfully 
implemented by the copper-catalyzed multicomponent synthesis of the indolizine nucleus followed by 
the platinum-catalyzed heterogeneous hydrogenation, without the need to isolate the intermediate 
indolizine. This approach represents a direct pathway to a new type of indolizidines. 
 
EXPERIMENTAL SECTION 
General: Platinum(IV) oxide (Acros), Pt(5 wt%)/C (Evonik) and Pd(20 wt%)/C (Evonik) were 
commercially available. Catalytic hydrogenation was carried out in a Parr hydrogenation apparatus 
using a 500 mL flask. Melting points are uncorrected. Infrared analysis was performed with a FT-IR 
spectrophotometer equipped with an ATR component; wavenumbers are given in cm–1. NMR spectra 
were recorded at 300 or 400 MHz for 1H NMR and 75 and 101 MHz for 13C NMR; chemical shifts are 
given in (δ) parts per million and coupling constants (J) in Hertz. Mass spectra (EI) were obtained at 70 
eV with a GC-MS apparatus; fragment ions in m/z with relative intensities (%) in parentheses. HRMS 
analyses were carried out in the electron impact mode (EI) at 70 eV using a quadrupole analyzer or 
with a LC-ESI-TOF system. Elemental analysis was performed on a CHNS microanalyzer. X-ray data 
collection was based on three ω-scan runs (starting ω = –34°) at the values of φ = 0°, 120°, 240° with 
the detector at 2θ = –32°. An additional run at φ = 0° of 100 frames was collected to improve 
redundancy. The diffraction frames were integrated using the SAINT program and the integrated 
 intensities were corrected for Lorentz-polarization effects with SADABS.32 The purity of volatile 
compounds and the chromatographic analyses (GLC) were determined with a gas chromatograph 
equipped with a flame ionization detector and a 30 m capillary column (0.32 mm diameter, 0.25 µm 
film thickness), using nitrogen (2 mL/min) as carrier gas, Tinjector = 270 ºC, Tcolumn = 60 ºC (3 min) and 
60–270 ºC (15 ºC/min); retention times (tR) are given in min. Thin-layer chromatography was carried 
out on TLC aluminum sheets covered with silica gel. Column chromatography was performed using 
silica gel of 40–60 microns (hexane/EtOAc as eluent). Preparative thin-layer chromatography was 
carried on laboratory-made TLC glass plates with silica gel 60 PF254 (hexane/EtOAc or EtOAc). 
 
General procedure for the synthesis of the indolizines 4: The indolizines 4 were prepared from 
pyridine-2-carbaldehyde derivatives, secondary amines and terminal alkynes according to our 
previously published procedure.24 The aldehyde (1, 0.5 mmol), amine (2, 0.5 mmol) and alkyne (3, 0.5 
mmol) were added to a reactor tube containing CuNPs/C (20 mg, ca. 0.5 mol%) and dichloromethane 
(1.0 mL). The reaction mixture was warmed to 70 ºC without the exclusion of air and monitored by 
TLC and/or GLC until total or steady conversion of the starting materials. The solvent was removed in 
vacuo; EtOAc (2 mL) was added to the resulting mixture followed by filtration through Celite and 
washing with additional EtOAc (4 mL). The reaction crude obtained after evaporation of the solvent 
was purified by column chromatography (silica gel, hexane/EtOAc) to give the corresponding 
indolizine 4. The physical and spectroscopic data of the new indolizine 4o follow: 
 
N,N-Dibenzyl-5-methyl-3-phenylindolizin-1-amine (4o): yellow oil (247 mg, 61%); tR 29.11; Rf 0.73 
(hexane/EtOAc, 8:2); IR (neat) ν 3079, 3066, 3027, 2925, 2827, 1599, 1492, 1472, 1451, 1292, 1070, 
748, 696; 1H NMR (300 MHz, CDCl3) δ 2.01(s, 3H), 4.17 (s, 4H), 6.13 (d, J = 6.5 Hz, 1H), 6.48 (dd, J 
= 8.8, 6.5 Hz, 1H), 6.55 (s, 1H), 7.14–7.29 (m, 11H), 7.37 (d, J = 7.0 Hz, 1H), 7.49 (d, J = 8.9 Hz, 1H); 
13C NMR (75 MHz, CDCl3) δ 23.0, 59.4, 111.4, 111.9, 114.7, 115.6, 126.7, 126.8, 127.0, 128.0, 128.6, 
 130.9, 123.5, 127.2, 134.0, 136.0, 139.6; MS (EI) m/z 402 (M+, 0.3), 311 (23), 310 (99), 309 (39), 295 
(10), 281 (18), 221 (10), 209 (13), 208 (24), 207 (100), 191 (17), 91 (26); HRMS (ESI) m/z: [M]+ Calcd 
for C29H26N2 402.2096; Found 402.2093. 
 
General procedure for the optimization of the catalytic hydrogenation: A suspension of the 
indolizine 4h (0.3 mmol) and catalyst (0.03 mmol) in glacial HOAc (3 mL) was hydrogenated at 
different pressures and reaction times, at room temperature, as indicated in Tables 1 and 2. The catalyst 
was removed by filtration and the resulting mixture was diluted with EtOAc and analyzed by GLC, 
TLC and GC-MS. 
 
General procedure for the hydrogenation of indolizines 4 catalyzed by PtO2: The indolizine 4 (0.5 
mmol) was poured into the hydrogenation flask, followed by the addition of PtO2 (11.4 mg, 10 mol%) 
and glacial HOAc (3 mL), with this mixture being subjected to hydrogenation at 3.74 atm (55 psi) and 
ambient temperature. The reaction was monitored by TLC and/or GLC until total or steady conversion 
of the starting material (see Table 2). The catalyst was separated by filtration and the solvent was 
removed under vacuum. Purification of the reaction crude by column chromatography (silica gel, 
hexane/EtOAc) afforded the pure indolizidines 5 as single diastereoisomers. 
 
(1R*,3R*,8aR*)-3-Phenyl-1-(piperidin-1-yl)octahydroindolizine (5a): yellow solid (83 mg, 58%); tR 
12.62; Rf 0.40 (hexane/EtOAc, 4:6); mp 68.9–70.9 ºC (EtOH); IR (neat) ν 3084, 3050, 3030, 2929, 
2851, 2789, 2789, 1601, 1439, 1364, 1260, 1142, 1126, 1105, 863, 755, 698; 1H NMR (400 MHz, 
CDCl3) δ 1.13–1.26, 1.34–1.66, 1.71–1.85, 1.98–2.11, 2.29–2.40, 2.67–2.86, 3.11–3.32 (7m, 22H), 
2.96 (t, J = 8.7 Hz, 1H), 7.19–7.25, 7.28–7.44 (2m, 5H); 13C NMR (101 MHz, CDCl3) δ 24.7, 24.8, 
25.6, 26.3, 26.6, 31.7, 51.7, 52.9, 65.3, 68.9, 70.2, 126.8, 127.4, 128.4, 143.8; MS (EI) m/z 284 (M+, 9), 
 201 (13), 174 (10), 173 (76), 172 (100), 110 (44); HRMS (ESI) m/z: [M + H]+ Calcd for C19H29N2 
285.2341; Found 285.2331. 
 
(1R*,3R*,8aR*)-1-(Piperidin-1-yl)-3-(p-tolyl)octahydroindolizine (5b): brown oil (52 mg, 35%); tR 
13.14; Rf 0.40 (hexane/EtOAc, 1:1); IR (neat) ν 3046, 3009, 2927, 2851, 2786, 2747, 1512, 1439, 
1260, 1143, 1126, 1105, 1036, 863, 813, 797, 735; 1H NMR (300 MHz, CDCl3) δ 1.15–1.86 (m, 14H), 
1.92–2.08 (m, 2H), 2.27–2.40 (m, 5H), 2.63–2.86 (m, 3H), 2.92 (t, J = 8.7Hz, 1H), 3.16 (ddd, m, J = 
9.0 Hz, 7.4, 3.8, 1H), 7.12 (d, J = 7.8 Hz, 2H), 7.23 (d, J = 7.8 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 
21.2, 24.8, 24.9, 25.6, 26.4, 26.6, 31.7, 51.8, 52.9, 65.4, 69.0, 70.0, 127.3, 129.1, 136.3, 140.9; MS (EI) 
m/z 298 (M+, 6), 215 (12), 188 (10), 187 (71), 186 (100), 110 (45); HRMS (ESI) m/z: [M + H]+ Calcd 
for C20H31N2 299.2487; Found 299.2500. 
 
(1R*,3R*,8aR*)-3-(4-Methoxyphenyl)-1-(piperidin-1-yl)octahydroindolizine (5c): this compound 
was isolated together with an inseparable impurity as a brown oil (71 mg, aprox. 45%); tR 14.20; Rf 
0.42 (hexane/EtOAc, 4:6); IR (neat) ν 3060, 2991, 2930, 2852, 2785, 2749, 1611, 1509, 1439, 1300, 
1242, 1179, 1170, 1143, 1126, 1101, 1036, 828, 798; Selected NMR data: 1H NMR (400 MHz, CDCl3) 
δ 1.06–1.91 (m, 15H), 1.94–2.09 (m, 2H), 2.26–2.49 (m, 2H), 2.73–2.81 (m, 2H), 2.91 (t, J = 8.7 Hz, 
1H), 3.12–3.30 (m, 1H), 3.80 (s, 3H), 6.84–6.89 (m, 2H), 7.21–7.32 (m, 2H); 13CNMR (101 MHz, 
CDCl3) δ 24.7, 24.8, 25.6, 26.2, 26.6, 31.7, 51.7, 52.8, 55.4, 65.2, 68.9, 69.7, 113.8, 128.4, 135.8, 
158.6; MS (EI) m/z 314 (M+, 6), 231 (15), 204 (11), 203 (76), 202 (100), 110 (47); HRMS (ESI) m/z: 
[M + H]+ Calcd for C20H31N2O 315.2436; Found 315.2435. 
 
4-[(1R*,3R*,8aR*)-3-Phenyloctahydroindolizin-1-yl]morpholine (5d): yellow solid (97 mg, 68%); tR 
12.69; Rf 0.34 (hexane/EtOAc, 8:2); mp 53.7–55.7 ºC (EtOH); IR (neat) ν 3079, 3060, 3030, 2939, 
2849, 2802, 2749, 1603, 1448, 1258, 1136, 1114, 998, 866, 755, 699; 1H NMR (300 MHz, CDCl3) δ 
 1.16–1.28, 1.34–1.38, 1.50–1.69, 1.71–1.88, 2.00–2.12, 2.31–2.51, 2.73–2.91 (7m, 15H; 7 × CH2, CH), 
2.30 (t, J = 8.7 Hz, 1H; CH), 3.06–3.23 (m, 1H; CH), 3.66–3.77 (m, 4H; 2 × CH2), 7.21–7.36 (m, 5H; 5 
× ArH); 13C NMR (75 MHz, CDCl3) δ 24.6, 25.6, 26.7, 31.8, 51.1, 52.9, 67.4 (9 × CH2), 65.1, 68.9, 
70.2 (3 × CH), 126.9, 127.3, 128.5 (5 × ArCH), 143.5 (ArC); MS (EI) m/z 286 (M+, 3), 203 (14), 173 
(71), 172 (100), 112 (41), 104 (10); Anal. Calcd for C18H26N2O: C, 75.48; H, 9.15; N, 9.78. Found: C, 
75.88; H, 9.28; N 9.94. 
 
(1R*,3R*,8aR*)-N-Benzyl-N-methyl-3-phenyloctahydroindolizin-1-amine (5e): brown oil; tR 14.14 
(96 mg, 60%); Rf 0.57 (hexane/EtOAc, 8:2); IR (neat) ν 3084, 3065, 3025, 2934, 2858, 2784, 1599, 
1492, 1449, 1361, 1262, 1147, 1099, 1071, 1019, 867, 755, 731, 697; 1H NMR (400 MHz, CDCl3) δ 
1.14–1.27, 1.36–1.48, 1.49–1.61, 1.69–1.80, 1.81–1.95, 2.10–2.19 (6m, 10H), 2.33 (s, 3H), 2.84 (d, J = 
10.6 Hz, 1H), 3.02 (t, J = 8.7 Hz, 1H), 3.34–3.47 (d, m, J = 13.8 Hz, 2H), 4.10 (d, J = 13.8 Hz, 1H), 
7.22–7.26, 7.28–7.40 (2m, 10H); 13C NMR (101 MHz, CDCl3) δ 24.8, 25.5, 26.7, 32.1, 52.8, 59.0, 
39.9, 63.1, 69.0, 70.1, 126.9, 127.0, 127.4, 128.4, 128.5, 128.9, 139.4, 143.5; MS (EI) m/z 320 (M+, 2), 
237 (13), 173 (76), 172 (100), 146 (46), 91 (35); HRMS (ESI) m/z: [M + H]+ Calcd for C22H29N2 
321.2335; Found 321.2331. 
 
(1R*,3R*,8aR*)-N-Methyl-N-phenethyl-3-phenyloctahydroindolizin-1-amine (5f): brown oil; tR 
15.50 (102 mg, 61%); Rf 0.66 (hexane/EtOAc, 4:6); IR (neat) ν 3084, 3065, 3025, 2933, 2848, 2784, 
2749, 1603, 1493, 1451, 1362, 1262, 1144, 1100, 1029, 934, 867, 802, 755, 697; 1H NMR (300 MHz, 
CDCl3) δ 1.19–1.89, 2.04–2.18 (2m, 10H), 2.42 (s, 3H), 2.44–2.63, 2.73–2.85, 2.94–3.11, 3.25–3.42 
(4m, 7H), 7.15–7.36 (m, 10H); 13C NMR (101 MHz, CDCl3) δ 24.8, 25.7, 26.9, 32.8, 35.0, 52.8, 57.2, 
40.1, 64.1, 69.2, 70.1, 125.9, 126.9, 127.4, 128.3, 128.4, 128.9, 141.1, 143.6; MS (EI) m/z 334 (M+, 1), 
251 (11), 243 (39), 173 (70), 172 (100), 160 (42), 139 (10), 91 (11); HRMS (ESI) m/z: [M + H]+ Calcd 
for C23H31N2 335.2487; Found 335.2490. 
 (1R*,3R*,8aR*)-N,N-Dibutyl-3-phenyloctahydroindolizin-1-amine (5g): brown oil (108 mg, 66%); 
tR 12.74; Rf 0.54 (hexane/EtOAc, 8:2); IR (neat) ν 3060, 3025, 2936, 2852, 2792, 1601, 1492, 1451, 
1363, 1263, 1145, 1027, 976, 755, 741, 731, 696; 1H NMR (300 MHz, CDCl3) δ 0.92 (t, J = 7.2 Hz, 
6H), 1.14–1.87, 2.01–2.15, 2.18–2.36, 2.75–2.86, (4m, 23H), 2.94 (t, J = 8.7 Hz, 1H), 3.29–3.45 (m, 
1H), 7.19–7.25 (m, 1H), 7.28–7.38 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 14.4, 20.9, 25.0, 25.8, 27.1, 
31.1, 34.1, 52.2, 52.8, 60.7, 69.5, 70.3, 126.8, 127.5, 128.4, 144.0; MS (EI) m/z 328 (M+, 4), 174 (10), 
173 (84), 172 (100), 154 (40), 140 (10), 117 (10), 91 (11); HRMS (ESI) m/z: [M + H]+ Calcd for 
C22H37N2 329.2961; Found 329.2957. 
 
(1R*,3R*,8aR*)-N,N-Dibenzyl-3-phenyloctahydroindolizin-1-amine (5h): 
brown oil (129 mg, 65%); tR 21.06; Rf 0.89 (hexane/EtOAc, 8:2); IR ν 3060, 
3025, 2936, 2852, 2792, 1601, 1492, 1451, 1363, 1263, 1145, 1027, 976, 
755, 741, 731, 696; 1HNMR (300 MHz, CDCl3) δ 1.14–1.25 (m, 1H; Hf), 
1.34–1.44 (m, 1H; He’), 1.46–1.59 (m, 2H; He, Hd’), 1.75–1.87 (m, 3H; Hb, Hf’, Hg), 1.88–1.95 (m, 
1H; Hg’), 1.99–2.08 (m, 1H; Hh), 2.08–2.19 (m, 1H; Hb’), 2.81 (d, J = 10.4 Hz, 1H; Hd), 2.98 (t, J = 8.8 
Hz, 1H; Hc), 3.28 (d, J = 14.8 Hz, 2H; 2 × Hi), 3.36 (td, J = 8.8, 4.0 Hz, 1H; Ha), 4.20 (br s, 2H; 2 × 
Hi’), 7.19–7.27 (m, 3H; 3 × ArH), 7.28–7.40 (m, 8H; 8 × ArH), 7.41–7.51 (m, 4H; 4 × ArH); 13C NMR 
(75 MHz, CDCl3) δ 24.8 (C-6), 25.6 (C-7), 27.0 (C-8), 32.4 (C-2), 52.9 (C-5), 56.1 (2 × C-9), 58.5 (C-
1), 69.1 (C-8a), 70.2 (C-3), 126.7, 126.9, 127.4, 128.4, 128.5 (15 × ArCH), 140.8, 143.7 (3 × ArC); MS 
(EI) m/z 396 (M+, 0.3), 306 (14), 305 (59), 222 (51), 174 (10), 173 (79), 172 (100), 117 (12), 91 (72); 
HRMS (ESI) m/z: [M + H]+ Calcd for C28H32N2 396.2565; Found 396.2585. 
 
(1R*,3R*,8aR*)-N,N-Dibenzyl-3-(p-tolyl)octahydroindolizin-1-amine (5i): brown oil (119 mg, 58%); 
tR 22.80; Rf 0.86 (hexane/EtOAc, 8:2); IR (neat) ν 3079, 3060, 3030, 2935, 2858, 2794, 2754, 1603, 
1493, 1451, 1362, 1263, 1145, 813, 770, 740, 728, 696; 1H NMR (400 MHz, CDCl3) δ 1.14–1.56, 
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 1.75–1.96, 1.99–2.16 (3 m, 10H), 2.35 (s, 3H), 2.80 (d, J = 10.6 Hz, 1H), 2.94 (t, J = 8.7 Hz, 1H), 3.28 
(d, J = 14.5 Hz, 2H), 3.31–3.40 (m, 1H), 4.19 (broad s, 2H), 7.12–7.16, 7.19–7.25, 7.25–7.34, 7.41–
7.53 (4m, 14H); 13C NMR (101 MHz, CDCl3) δ 21.3, 24.8, 25.6, 27.0, 32.4, 52.9, 56.1, 58.5, 69.1, 
69.9, 126.7, 127.3, 128.3, 128.5, 129.2, 136.5, 140.7, 140.8; MS (EI) m/z 410 (M+, 0.2), 320 (10), 319 
(41), 236 (31), 222 (10), 188 (11), 187 (77), 186 (97), 131 (12), 118 (14), 117 (11), 106 (10), 105 (27), 
91 (100); HRMS (ESI) m/z: [M + H]+ Calcd for C29H35N2 411.2800; Found 411.2813. 
 
(1R*,3R*,8aR*)-N,N-Dibenzyl-3-(4-methoxyphenyl)octahydroindolizin-1-amine (5j): brown oil 
(183 mg, 86%); tR 31.39; Rf 0.26 (hexane/EtOAc, 8:2); IR (neat) ν 3060, 3025, 2934, 2851, 2832, 
2791, 2752, 1610, 1509, 1242, 1170, 1145, 1101, 1036, 828, 740, 728, 697; 1H NMR (300 MHz, 
CDCl3) δ 1.11–1.55, 1.76–2.15 (2m, 10H), 2.79 (d, J = 10.4 Hz, 1H), 2.91 (t, J = 8.7 Hz, 1H), 3.20–
3.43 (d, m, J= 14.4 Hz, 3H), 3.81 (s, 3H), 3.93–4.45 (m, 2H), 6.86–6.92, 7.18–7.26, 7.28–7.36, 7.42–
7.54 (4m, 14H); 13C NMR (75 MHz, CDCl3) δ 24.9, 25.6, 27.0, 32.3, 52.8, 56.1, 55.4, 58.4, 69.1, 69.6, 
113.9, 126.7, 128.3, 128.4, 128.5, 135.7, 140.8, 158.7; MS (EI) m/z 426 (M+, 0.3), 343 (10), 336 (18), 
335 (74), 252 (35), 222 (23), 204 (13), 203 (91), 202 (100), 134 (10), 121 (47), 91 (75); HRMS (ESI) 
m/z: [M + H]+ Calcd for C29H35N2O 427.2749; Found 427.2763. 
 
Methyl 4-[(1R*,3R*,8aR*)-1-(dibenzylamino)octahydroindolizin-3-yl)]benzoate (5k): white solid 
(216 mg, 95%); Rf 0.60 (hexane/EtOAc, 8:2); mp 144.5–147.6; IR (neat) ν 3058, 2945, 2792, 1719, 
1274, 1110, 1097, 769, 733, 697; 1H NMR (300 MHz, CDCl3) δ 1.16–1.61 (m, 4H), 1.76–1.95 (m, 
4H), 2.04–2.19 (m, 2H), 2.79 (d, J = 10.7 Hz, 1H), 3.06 (t, J = 8.7 Hz, 1H), 3.24 (d, J = 14.4 Hz, 2H), 
3.39 (td, J = 8.7, 3.9 Hz, 1H), 3.92 (s, 3H), 4.17 (br s, 2H), 7.23 (t, J = 7.3 Hz, 2H), 7.32 (t, J = 7.5 Hz, 
4H), 7.45 (m, 6H), 8.02 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 24.6, 25.4, 26.8, 32.1, 52.0, 52.8, 55.8, 
58.5, 69.0, 69.6, 126.6, 127.1, 128.2, 128.3, 129.8, 128.7, 140.4, 149.2, 167.1; MS (EI) m/z 454 (M+, 
 0.4), 364 (18), 363 (72), 281 (13), 280 (65), 232 (14), 231 (100), 230 (96), 222 (10), 216 (20), 91 (70); 
Anal. Calcd for C30H34N2O2: C, 79.26; H, 7.54; N, 6.16. Found: C, 78.80; H, 7.48; N, 6.11. 
 
(1R*,3R*,8aR*)-N,N-Dibenzyl-3-[4-(trifluoromethyl)phenyl]octahydroindolizin-1-amine (5l): beige 
solid (128 mg, 55%); tR 19.28; Rf 0.80 (hexane/EtOAc, 7:3); mp 141.6–144.4 ºC; IR (neat) ν 3079, 
3060, 3030, 2937, 2853, 2792, 2754, 1617, 1322, 1161, 1121, 1102, 1066, 1018, 834, 739, 729, 697; 
1H NMR (300 MHz, CDCl3) δ 1.13–1.64, 1.74–1.99, 2.05–2.22 (3m, 10H), 2.79 (d, J = 10.5 Hz, 1H), 
3.06 (t, J = 8.7 Hz, 1H), 3.24 (d, J = 14.4 Hz, 2H), 3.32–3.49 (m, 1H), 3.97–4.42 (m, 2H), 7.20–7.26, 
7.29–7.36, 7.43–7.52, 7.58–7.63 (4m, 14H); 13C NMR (75 MHz, CDCl3) δ 24.7, 25.5, 27.0, 32.3, 52.9, 
56.0, 58.6, 69.1, 69.7, 124.4 (q, 1JC-F = 271.9 Hz), 125.5 (q, 3JC-F = 3.8 Hz), 126.8, 127.6, 128.4, 128.5, 
129.1 (q, 2JC-F = 32.1 Hz), 140.5, 148.0; MS (EI) m/z 464 (M+, 0.1), 373 (39), 291 (10), 290 (54), 242 
(11), 241 (78), 240 (100), 172 (11), 91 (82); Anal. Calcd for C29H31F3N2: C, 74.98; H, 6.73; N, 6.03. 
Found: C, 74.95; H, 6.75; N, 5.90. 
 
(1R*,3S*,8aR*)-N,N-Dibenzyl-3-decyloctahydroindolizin-1-amine (5m): brown oil (166 mg, 72%); 
tR 25.57; Rf 0.83 (hexane/EtOAc, 7:3); IR ν 3079, 3060, 3020, 2922, 2852, 2791, 2754, 1603, 1493, 
1452, 1364, 1263, 1148, 1027, 981, 938, 771, 733, 696; 1H NMR (300 MHz, CDCl3) δ 0.89 (t, J = 6.7 
Hz, 3H), 1.07–1.45, 1.47–1.89 (2m, 29H), 3.08–3.16, 3.17–3.25 (2m, 2H), 3.29 (d, J = 14.6 Hz, 2H), 
3.84–4.29 (m, 2H), 7.17–7.23, 7.26–7.33, 7.39–7.50 (3m, 10H); 13C NMR (75 MHz, CDCl3) δ 14.3, 
22.9, 25.1, 25.7, 26.8, 27.0, 28.0, 29.5, 29.8, 29.9, 30.3, 32.1, 32.8, 53.0, 56.1, 58.0, 65.6, 69.8, 126.6, 
128.3, 128.4, 140.9; MS (EI) m/z 460 (M+, 0.4), 370 (20), 369 (71), 238 (18), 237 (100), 236 (50), 166 
(12), 138 (12), 124 (42), 122 (18), 111 (17), 110 (51), 98 (11), 97 (21), 96 (13), 91 (72), 84 (12); Anal. 
Calcd for C32H48N2: C, 83.42; H, 10.50; N, 6.08. Found: C, 83.81; H, 10.23; N, 5.73. 
 
 (1R*,3R*,8aR*)-N,N-Dibutyl-1-phenyl-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinolin-3-amine (5n): 
yellow oil (85 mg, 45%), tR 21.37; Rf 0.75(hexane/EtOAc, 9:1); IR (neat) ν 3021, 2957, 2921, 2856, 
2816, 1598, 1491, 1455, 1320, 1097, 1079, 1029, 803, 751, 703; 1H NMR (300 MHz, CDCl3) δ 0.87 (t, 
J = 7.2 Hz, 6H; 2 × CH3), 1.14–1.43 (m, 8H; 4 × CH2), 1.94 (ddd, J = 14.0, 6.5, 3.6 Hz, 1H; CH), 
2.06–2.19 (m, 4H; 2 × CH2), 2.52–2.65 (m, 3H), 2.92–3.00 (m, 2H), 3.36–3.52 (m, 2H), 4.35 (dd, J = 
9.8, 6.5 Hz, 1H; CH), 6.14 (dd, J = 8.1, 0.9 Hz, 1H; ArH), 6.64 (td, J = 7.3, 1.1 Hz, 1H; ArH), 6.79 (td, 
J = 8.2, 1.7 Hz, 1H; ArH), 7.05 (dd, J = 7.4, 1.2 Hz, 1H; ArH), 7.17–7.29 (m, 5H; ArH); 13C NMR (75 
MHz, CDCl3) δ 14.2 (2 × CH3), 20.6, 24.5, 27.9, 30.3, 36.1, 51.8 (9 × CH2), 60.7, 63.2, 64.2 (3 × CH), 
114.9, 117.9, 125.9, 126.3, 128.1, 128.3, 128.7 (9 × ArCH), 125.6, 144.0, 146.9 (3 × ArC); MS (EI) 
m/z 376 (M+, 18), 329 (9), 247 (11), 246 (12), 245 (20), 244 (30), 221 (55), 220 (100), 202 (20), 155 
(11), 154 (72), 117 (25), 115 (12), 91 (11); HRMS (ESI) m/z: [M+] Calcd for C26H36N2 376.2878; 
Found 376.2889. 
 
(1R*,3R*,5R*,8aR*)-N,N-Dibenzyl-5-methyl-3-phenyloctahydroindolizin-1-amine (5o): yellow oil 
(82 mg, 40%), tR 28.22; Rf 0.83 (hexane/EtOAc, 8:2); IR (neat) ν 3027, 2926, 2849, 2797, 1492, 1452, 
1140, 993, 732, 697, 617; 1H NMR (300 MHz, CDCl3) δ 0.54 (d, J = 6.4 Hz, 3H), 1.18–1.44 (m, 5H), 
1.72–1.95 (m, 5H), 2.14–2.25 (m, 2H), 3.21 (d, J = 14.2 Hz, 2H; CH2), 3.23 (t, J = 4.4 Hz, 1H), 3.28 
(ddd, J = 9.5, 7.9, 3.6 Hz, 1H), 4.23 (d, J = 14.2 Hz, 2H; CH2), 7.18–7.25 (m, 3H; 3 × ArH), 7.29–7.34 
(m, J = 7.5 Hz, 8H; 8 × ArH), 7.46 (d, J = 7.5 Hz, 4H; 4 × ArH); 13C NMR (75 MHz, CDCl3) δ 23.3 
(CH3), 25.3, 27.3, 34.2, 35.6 (4 × CH2), 55.9 (2 × CH2N), 58.5, 62.9, 69.8, 70.8 (4 × CH), 126.2, 
126.6, 126.7, 128.1, 128.4 (15 × ArCH), 140.1, 148.0 (3 × ArC); MS (EI) m/z 319 (73), 222 (49), 207 
(20), 187 (64), 186 (89), 117 (14), 106 (10), 104 (12), 92 (11), 91 (100); HRMS (ESI) m/z: [M+] Calcd 
for C29H34N2 410.2722, [M – Bn]+ 319.2174; Found 319.2195. 
 
 General procedure for the hydrogenolysis of indolizines 5 to monobenzylated indolizidines 6: The 
indolizine 5 (0.3 mmol) was poured into the hydrogenation flask, followed by the addition of Pt(5 
wt%)/C (117 mg, 10 mol%) or PtO2 (11.4 mg, 10 mol%) and glacial HOAc (3 mL), with this mixture 
being subjected to hydrogenation at ca. 1 atm (balloon) and ambient temperature. The reaction was 
monitored by TLC and/or GLC until total or steady conversion of the starting material (see Table 3). 
The catalyst was separated by filtration and the glacial HOAc was neutralized with 2M NaOH, 
followed by extraction with EtOAc, drying of the organic phase with Na2SO4 and solvent evaporation 
under vacuum. Purification of the reaction crude by preparative TLC (silica gel, hexane/EtOAc 6:4) 
afforded the pure indolizidines 6 as single diastereoisomers. 
 
(1R*,3R*,8aR*)-N-Benzyl-3-phenyloctahydroindolizin-1-amine (6h): brown oil (63 mg, 68%); tR 
15.38; Rf 0.44 (hexane/EtOAc, 3:7); IR (neat) ν 3029, 2935, 2851, 2789, 1603, 1492, 1451, 1145, 
1117, 754, 731, 609; 1H NMR (300 MHz, CDCl3) δ 1.15–1.31 (m, 1H), 1.38–1.86 (m, 8H), 2.06–2.15 
(m, 1H), 2.43 (dt, J = 13.5, 8.0 Hz, 1H), 2.83, (d, J = 10.7 Hz, 1H), 3.07 (t, J = 8.4 Hz, 1H), 3.14 (ddd, 
J = 7.9, 6.1, 3.1 Hz, 1H), 3.68, 3.86 (AB system, J = 13.4 Hz, 2H), 7.20–7.37 (m, 10H); 13C NMR (75 
MHz, CDCl3) δ 24.4, 25.4, 26.4, 41.7, 51.4, 52.1, 57.5, 68.8, 69.9, 126.8, 126.9, 127.6, 128.1, 128.3, 
140.7, 143.3; MS (70 eV) m/z (%) 306 (M+, 3), 223 (20), 197 (21), 196 (20), 173 (61), 172 (100), 168 
(11), 132 (29), 91 (25); HRMS (EI) m/z: Calcd for C21H26N2 306.2096; Found 306.2092. 
 
(1R*,3R*,8aR*)-N-Benzyl-3-(4-methoxyphenyl)octahydroindolizin-1-amine (6j): brown oil; (73 mg, 
72%); tR 18.52; Rf 0.13 (hexane/EtOAc, 6:4); IR (neat) ν 3060, 2951, 2851, 1509, 1426, 1301, 1259, 
1112, 896, 734, 698; 1H NMR (300 MHz, CDCl3) δ 1.19–1.92 (m, 9H), 2.02–2.13 (m, 1H), 2.41 (dt, J 
= 13.5, 8.0 Hz, 1H), 2.81 (d, J = 10.7 Hz, 1H), 3.02 (t, J = 8.4 Hz, 1H), 3.14 (ddd, J = 7.8, 6.1, 3.1 Hz, 
1H), 3.69, 3.87 (AB system, J = 13.4 Hz, 2H), 3.80 (s, 3H), 6.86 (d, J = 8.4 Hz, 2H), 7.21–7.36 (m, 
7H); 13C NMR (75 MHz, CDCl3) δ 24.3, 25.3, 26.3, 41.6, 51.4, 52.0, 55.2, 57.4, 68.8, 69.4, 113.7, 
 126.8, 128.1, 128.3, 128.7, 135.0, 140.6, 158.6; MS (70 eV) m/z (%) 336 (M+, 2), 253 (21), 252 (10), 
231 (10), 227 (39), 226 (13), 212 (17), 207 (13), 203 (58), 202 (100), 162 (34), 135 (12), 134 (20), 132 
(39), 106 (16), 92 (10), 91 (66), 84 (12), 77 (14), 65 (10); HRMS (EI) m/z: Calcd for C22H28N2O 
336.2202; Found 336.2185. 
 
(1R*,3R*,8aR*)-N-Benzyl-3-[4-(trifluoromethyl)phenyl]octahydroindolizin-1-amine (6l): brown oil 
(73 mg, 65%); tR 15.06; Rf 0.48 (hexane/EtOAc, 6:4); IR (neat) ν 3029, 2934, 2852, 2789, 2753, 1509, 
1325, 1162, 1119, 1018, 837, 731, 697; 1H NMR (300 MHz, CDCl3) δ 1.08–1.99 (m, 9H), 2.07–2.29 
(m, 1H), 2.34–2.61 (m, 1H), 2.80 (d, J = 10.7 Hz, 1H), 3.08–3.21 (m, 2H), 3.67, 3.84 (AB system, J = 
13.3 Hz, 2H), 7.20–7.35 (m, 5H), 7.47, 7.56 (AA’BB’system, J = 8.2 Hz, 4H); 13C NMR (75 MHz, 
CDCl3) δ 24.2, 25.3, 26.4, 41.8, 51.5, 52.1, 57.7, 68.7, 69.3, 124.3 (q, J = 271.8 Hz) 125.3 (q, J = 3.7 
Hz), 126.8, 127.8, 128.1, 128.3, 129.1 (q, J = 32.2 Hz) 140.7, 147.9; MS (70 eV) m/z (%) 374 (M+, 2), 
291 (8), 269 (11), 242 (10), 241 (62), 240 (100), 172 (11), 132 (20), 91 (38), 84 (27); HRMS (EI) m/z: 
Calcd for C22H25F3N2 374.1970; Found 374.1967. 
 
(1R*,3R*,8aR*)-N-Benzyl-3-decyloctahydroindolizin-1-amine (6m): brown oil (90 mg, 81%); tR 
19.19; Rf 0.20 (hexane/EtOAc, 3:7); IR (neat) ν 3029, 2922, 2852, 2817, 1566, 1454, 1145, 980, 743, 
698; 1H NMR (300 MHz, CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.09–1.40 (m, 20H), 1.43–2.04 (m, 9H), 
2.2 (dt, J = 13.1, 7.8 Hz, 1H), 2.96–3.07 (m, 1H), 3.19 (d, J = 10.5 Hz, 1H), 3.65, 3.84 (AB system, J = 
13.4 Hz, 2H), 7.17–7.35 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 14.1, 22.7, 24.6, 25.2, 26.2, 26.6, 29.3, 
29.6, 30.0, 31.9, 38.0, 51.6, 52.2, 56.9, 65.3, 69.4, 126.6, 128.1, 128.2, 140.7; MS (70 eV) m/z (%) 370 
(M+, 3), 261 (9), 238 (13), 237 (49), 236 (23), 229 (28), 135 (14), 134 (100), 132 (12), 124 (27), 111 
(10), 110 (27), 97 (11), 91 (25); HRMS (EI) m/z: Calcd for C25H42N2 370.3348; Found 370.3337. 
 
 General procedure for the hydrogenolysis of indolizines 5 to debenzylated indolizidines 7: The 
indolizine 5 (0.3 mmol) was poured into the hydrogenation flask, followed by the addition of Pd(20 
wt%)/C (16 mg, 10 mol%) and glacial HOAc (3 mL), with this mixture being subjected to 
hydrogenation at ca. 1 atm (balloon) and ambient temperature. The reaction was monitored by TLC 
and/or GLC until total or steady conversion of the starting material (see Table 3). The catalyst was 
separated by filtration and the glacial HOAc was neutralized with 2M NaOH, followed by extraction 
with EtOAc, drying of the organic phase with Na2SO4 and solvent evaporation under vacuum. 
Compounds 7j and 7m did not require any further purification; compounds 7h and 7l were purified by 
preparative TLC (EtOAc). In all cases, the pure indolizidines 7 were obtained as single 
diastereoisomers. 
 
(1R*,3R*,8aR*)-3-Phenyloctahydroindolizin-1-amine (7h): yellow oil (55 mg, 85%); tR 11.11; Rf 
0.20 (EtOAc/MeOH, 8:2); IR (neat) ν 3038, 2932, 2854, 1555, 1455, 1388, 1311, 1145, 754, 698; 1H 
NMR (300 MHz, CDCl3) δ 1.21–1.62 (m, 6H), 1.63–1.88 (m, 3H), 2.02 (ddd, J = 7.5, 5.4, 2.7 Hz, 2H), 
2.62 (ddd, J = 14.0, 8.8, 8.0 Hz, 1H), 2.83 (d, J = 10.8 Hz, 1H), 3.07 (t, J = 8.4 Hz, 1H), 3.27 (ddd, J = 
7.7, 5.1, 2.4 Hz, 1H), 7.15–7.26 (m, 1H), 7.28–7.36 (m, 4H); 13C NMR (75 MHz, CDCl3) δ 23.9, 25.2, 
26.0, 43.9, 51.7, 52.3, 68.6, 69.4, 126.8, 127.4, 128.2, 143.2; MS (70 eV) m/z (%) 217 (M++1, 1), 216 
(M+, 8), 173 (51), 172 (100), 132 (8), 104 (7), 84 (15); HRMS (EI) m/z: Calcd for C14H20N2 216.1626, 
C14H17N [M+ – NH3] 199.1361; Found 199.1356. 
 
(1R*,3R*,8aR*)-3-(4-Methoxyphenyl)octahydroindolizin-1-amine (7j): brown oil (57 mg, 77%); tR 
12.59; Rf 0.17 (acetone); IR (neat) ν 2933, 2851, 1583, 1242, 1035, 828, 626; 1H NMR (300 MHz, 
CDCl3) δ 0.95–2.01 (m, 9H), 2.57 (dt, J = 13.9, 8.4 Hz, 1H), 2.73 (s, 2H), 2.8 (d, J = 10.8 Hz, 1H), 
2.99 (t, J = 8.4 Hz, 1H), 3.27 (ddd, J = 7.9, 5.2, 2.5 Hz, 1H), 3.78 (s, 3H), 6.85, 7.24 (AA’XX’, J = 8.7 
Hz, 4H); 13C NMR (75 MHz, CDCl3) δ 23.9, 25.2, 25.9, 43.7, 51.6, 52.1, 55.1, 68.6, 69.0, 113.6, 
 128.5, 134.9, 158.5; MS (70 eV) m/z (%) 247 (M++1, 3), 246 (M+, 17), 203 (48), 202 (100), 162 (11), 
134 (16), 132 (11), 84 (43); HRMS (EI) m/z: Calcd for C15H22N2O 246.1732; Found 246.1723. 
 
(1R*,3R*,8aR*)-3-[4-(Trifluoromethyl)phenyl]octahydroindolizin-1-amine (7l): yellow oil (63 mg, 
74%); tR 10.99; Rf 0.45 (EtOAc/MeOH, 8:2); IR (neat) ν 3024, 2939, 2851, 1553, 1457, 1322, 1162, 
1117, 1066, 838; 1H NMR (300 MHz, CDCl3) δ 1.29–1.60 (m, 4H), 1.73–1.89 (m, 3H), 2.12 (ddd, J = 
10.9, 4.9, 2.4 Hz, 1H), 2.60–2.83 (m, 5H), 3.19 (t, J = 8.5 Hz, 1H), 3.37–3.42 (m, 1H), 7.46, 7.57 
(AA’XX’ system, J = 8.2 Hz, 4H); 13C NMR (75 MHz, CDCl3) δ 23.9, 25.2, 26.0, 44.2, 51.7, 52.5, 
68.7, 68.9, 124.2 (q, J = 272.0 Hz), 125.3 (q, J = 3.6 Hz), 127.6, 129.0 (q, J = 32.0 Hz), 147.8; MS (70 
eV) m/z (%) 285 (M++1, 1), 284 (M+, 5), 265 (7), 242 (8), 241 (62), 240 (100), 200 (6), 172 (9), 84 
(12); HRMS (EI) m/z: Calcd for C15H19F3N2 284.1500, C15H16F3N [M+ – NH3] 267.1235; Found 
267.1221. 
 
(1R*,3R*,8aR*)-3-Decyloctahydroindolizin-1-amine (7m): brown oil (77 mg, 92%); tR 15.44; Rf 0.20 
(EtOAc/MeOH, 7:3); IR (neat) ν 2921, 2851, 1560, 1467, 1458, 1387, 1147, 1121, 811, 721, 687; 1H 
NMR (300 MHz, CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.06 (ddd, J = 13.6, 8.1, 2.7 Hz, 1H), 1.20–1.85 
(m, 27H), 2.04–2.19 (m, 2H), 2.35 (dt, J = 13.6, 8.3 Hz, 1H), 3.12–3.20 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 14.1, 22.6, 24.2, 25.2, 25.9, 26.4, 29.3, 29.6, 29.9, 31.9, 33.5, 40.2, 52.1, 51.8, 65.0, 69.5; MS 
(70 eV) m/z (%) 280 (M++1, 1), 279 (M+, 1), 237 (16), 236 (11), 140 (10), 139 (100), 124 (17), 122 
(15), 110 (25), 96 (11); Anal. Calcd for C18H36N2: C, 77.08; H, 12.94; N, 9.99. Found: C, 76.72; H, 
12.65; N, 9.50. 
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